Chronic Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-03-09Clinical Trial Update: EHealth Educational Intervention to Improve Self-Management and Coping Behaviors Among Cancer Patients [NA]
A completed clinical trial evaluating an eHealth educational intervention to improve self-management and coping behaviors among cancer patie…
-
CLINICAL_TRIALS trial_result · 2026-03-06Clinical Trial Update: Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders [NA]
This update reports the completed status of a trial assessing bone marrow and kidney transplant for patients with chronic kidney disease and…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia [Phase 2]
This Phase 2 clinical trial update reports on a combination therapy of ibrutinib, fludarabine phosphate, cyclophosphamide, and obinutuzumab …
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating ixazomib citrate with rituximab in indolent B-cell non-Hodgkin lymphoma has posted results.
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia [Phase 2]
A Phase 2 clinical trial evaluating a vaccine booster GEO-CM04S1 to prevent COVID-19 in patients with chronic lymphocytic leukemia, currentl…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-03-04Clinical Trial Update: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) [Phase 1, Phase 2]
Clinical Trial Update on the ALPHA2 Phase 1/2 study evaluating ALLO-501A anti-CD19 allogeneic CAR T cells in adults with relapsed/refractory…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: HEALTH4CLL2: A Randomized Waitlist Control Trial of Behavioral Interventions in Patients With Chronic Lymphocytic Leukemia [NA]
HEALTH4CLL2 is a randomized waitlist-controlled trial evaluating behavioral interventions for patients with chronic lymphocytic leukemia. Th…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
BeiGene's BGB-11417 is being studied in a Phase 2 trial for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphom…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) [Phase 1, Phase 2]
This clinical trial evaluates the safety and efficacy of JCAR017 in relapsed or refractory chronic lymphocytic leukemia and small lymphocyti…
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome [Phase 2]
A Phase 2 clinical trial update evaluating the combination of zanubrutinib and lisocabtagene maraleucel for Richter's syndrome, with patient…
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Study of Oral LOXO-338 in Patients With Advanced Blood Cancers [Phase 1]
Phase 1 study of oral LOXO-338 in advanced blood cancers is ongoing, with status listed as active but not recruiting.
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias [Phase 1, Phase 2]
Clinical trial update on an anti-CD19 CAR-T cell therapy being evaluated in Phase 1/Phase 2 for various leukemias and lymphoid cancers; recr…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: National Acalabrutinib Observational Study
A national observational study of acalabrutinib in chronic lymphocytic leukemia is updated and currently active but not recruiting.
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib [Phase 4]
This document describes a Phase 4 master protocol studying the long-term safety of Pirtobrutinib (LY3527727). The study is currently recruit…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma [Phase 4]
This clinical trial update reports a Phase 4 study of pirtobrutinib (LY3527727) in previously treated chronic lymphocytic leukemia/small lym…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
A Mayo Clinic-sponsored clinical trial (HALT) is evaluating strategies to manage hypertension and prevent cardiovascular adverse events in p…
-
CLINICAL_TRIALS trial_result · 2026-02-25Clinical Trial Update: Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia [Phase 2]
A Phase 2 study evaluating Bendamustine/Rituximab followed by Venetoclax and Rituximab for chronic lymphocytic leukemia has completed.
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period [Phase 2]
Phase 2 study assessing venetoclax in combination with a covalent BTK inhibitor for first-line chronic lymphocytic leukemia to achieve deep,…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab [Phase 2]
This Phase 2 clinical trial update investigates initial therapy with zanubrutinib and venetoclax, with obinutuzumab added based on response,…
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies [Phase 1, Phase 2]
A first-in-human study evaluating HLA partially to fully matched allogeneic, cryopreserved deceased donor bone marrow transplantation for va…
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT) [Phase 2]
A Phase 2 clinical trial is evaluating a time-limited triplet therapy of pirtobrutinib, venetoclax, and obinutuzumab for treatment-naïve chr…
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) [Phase 2]
Phase 2 clinical trial of venetoclax for relapsed or refractory chronic lymphocytic leukemia is currently recruiting, with a focus on early …
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating CAR-20/19-T cells in relapsed or refractory B-cell malignancies, including multiple non-Hodgkin lymphoma…
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab [Phase 1, Phase 2]
BeiGene announced completion and posted results for a Phase 1/2 study of BGB-10188 as monotherapy and in combination with zanubrutinib and t…
-
FDA approval · 2026-02-19FDA Approved: CALQUENCE — Supplemental Application (AstraZeneca Pharmaceuticals LP)
FDA approves a supplemental application for CALQUENCE (acalabrutinib) submitted by AstraZeneca Pharmaceuticals LP.